Walmark a.s. has acquired the Sinulan Forte brand from Novascon Pharmaceuticals to strengthen its presence in the Polish dietary supplements market, particularly in the respiratory health category.
Target Information
Walmark a.s. is a prominent dietary supplements manufacturer operating in Central and Eastern Europe. Recently, the Company announced the acquisition of the Sinulan Forte brand from Novascon Pharmaceuticals. This acquisition positions Walmark to enhance its product offerings, specifically in the sinuses and upper respiratory health segment, where Sinulan is recognized as a leading brand in the Polish food supplements market.
By integrating Sinulan into its portfolio, Walmark aims to leverage the brand's established reputation and market presence to attract a broader customer base and increase sales in this vital category.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Poland
Poland's dietary supplements market has witnessed significant growth in recent years, driven by an increasing awareness of health and wellness among consumers. With a
Similar Deals
Scanmed → Centrum Rehabilitacji Sp. z o.o.
2024
Skupina BHM → FAMED Żywiec
2023
Scanmed → Med-Lux Sp. z o.o.
2023
Labnet International, Inc. → PZ HTL S.A.
2023
THC → Centrum Medycznym Med-Gastr
Walmark a.s.
invested in
Sinulan Forte
in 2023
in a Buy & Build / Roll-Up deal